Public health guidance on active case finding of communicable diseases in prison settings
This joint guidance from ECDC and the European Monitoring Centre for Drugs and Drug Addiction provides EU/EEA Member States with evidence-based scientific advice on active case finding options. These options can be applied to the planning and implementation of interventions that promote the early diagnosis of communicable diseases in prison settings.
ECDC and EMCDDA make the case for active case finding of communicable diseases in prison
In their joint public health Guidance published today, ECDC and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), present the evidence on active case finding as a key measure to diagnose communicable diseases early.
EU/EEA capacity for the surveillance of hepatitis B and C using molecular methods
In order to explore whether the current capacity for EU/EEA-wide molecular characterisation for surveillance of HBV and HCV is sufficient to be feasible and what gaps need to be addressed, a survey of EU/EEA Member States was conducted to assess their laboratory capacity and needs in relation to the molecular characterisation of hepatitis B and C.
Hepatitis B - Annual Epidemiological Report for 2015
In 2015, 30 EU/EEA Member States reported 24 573 cases of hepatitis B virus (HBV) infection, a crude rate of 4.7 cases per 100 000 population.
Systematic review on active case finding of communicable diseases in prison settings
The objective of this report is to systematically review the evidence on active case finding in prison settings, with a focus on the European Union (EU) and the European Economic Area (EEA) region.
ECDC-EMCDDA review: Can active case finding help reduce communicable diseases in prisons?
ECDC and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) have systematically retrieved and assessed evidence on active case findings for blood-borne viruses like HIV, hepatitis B and C, sexually transmitted infections as well as tuberculosis in prison settings in the EU/EEA.
ECDC: around 9 million Europeans are affected by chronic hepatitis B or C
An estimated 4.7 million Europeans are living with chronic hepatitis B and almost 4 million (3.9) with chronic hepatitis C infection. However, large numbers of them are not even aware of their infection as they have not yet been tested and diagnosed.